SEC Form 4 · accession 0001209191-18-058651
Travere Therapeutics, Inc. · TVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William E. Rote
Officer — Senior Vice President, R&D
Period of report
Nov 9, 2018
Accepted (ET)
Nov 14, 2018 · 8:45 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001438533
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Nov 9, 2018 | A | 5,000 | $0.00 | A | 22,992 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On February 13, 2017, the reporting person was granted performance restricted stock units (PRSUs) covering 15,000 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On November 9, 2018, a portion of the PRSUs vested upon the Issuer's confirmation that the US Food and Drug Administration had accepted for review a New Drug Application filed by the Issuer's partner.
- F2Includes 336 shares of the Issuer's common stock acquired by the reporting person on May 31, 2018 pursuant to an employee stock purchase program.